News | February 16, 2024
Marksans Q3 FY24 revenue up 22% at Rs 586 Cr
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
The company has received five final approvals
Ami Organics recently announced contract with global MNC for manufacturing of electrolyte for battery cells
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
Subscribe To Our Newsletter & Stay Updated
